Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinoma-An Emerging Role for Chemokines.
chemokines
clinical outcome
cytokines
esophageal adenocarcinoma
prognostic markers
serum markers
survival
treatment response
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Nov 2020
13 Nov 2020
Historique:
received:
02
10
2020
revised:
10
11
2020
accepted:
12
11
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor prognosis and incidence is increasing rapidly in the Western world. Multi-modal treatment has improved survival outcomes but only for a minority of patients. Currently no markers have been identified to predict treatment response. This study investigated the association between clinical outcomes and pre-treatment levels of 54 serum proteins in n = 80 patients with EAC. Low tumor regression grade (TRG), corresponding to a favorable treatment response, was linked to prolonged overall survival (OS). CCL4 was higher in patients with a favorable treatment response, while Tie2 and CRP were higher in poor responders. Elevated CCL22 and CCL26 was associated with improved OS, while elevated IL-10 showed a negative association. CCL3, CCL4, IL-1α and IL-12/IL23p40 were highest in individuals with no adverse features of tumor biology, whereas levels of Tie2 and VEGF were lowest in this cohort. CCL4 was also elevated in patients with high tumor lymphocyte infiltration. Comparison of matched pre- and post-treatment serum (n = 28) showed a large reduction in VEGFC, and a concomitant increase in other cytokines, including CCL4. These data link several serum markers with clinical outcomes, highlighting an important role for immune cell trafficking in the EAC antitumor immune response.
Identifiants
pubmed: 33202734
pii: cancers12113356
doi: 10.3390/cancers12113356
pmc: PMC7698106
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Health Research Board
ID : HRB-ILP-2017-055
Pays : Ireland
Organisme : Health Research Board
ID : HRA-POR-2015-1143
Pays : Ireland
Références
Nat Rev Cancer. 2020 Apr;20(4):203-217
pubmed: 32161398
Cancer. 2013 Mar 15;119(6):1149-58
pubmed: 23303625
Science. 2015 Nov 20;350(6263):972-8
pubmed: 26516201
Onkologie. 2005 May;28(5):281-8
pubmed: 15867486
J Surg Oncol. 2011 Jan 1;103(1):62-8
pubmed: 21031427
Gut. 2011 Nov;60(11):1449-72
pubmed: 21705456
World J Gastroenterol. 2013 Dec 28;19(48):9282-93
pubmed: 24409055
J Surg Oncol. 2016 Jun;113(7):732-7
pubmed: 27004839
Oncoimmunology. 2016 Sep 30;5(11):e1238541
pubmed: 27999757
J Surg Res. 2017 May 1;211:266-278
pubmed: 28501127
Mol Cancer Res. 2010 Nov;8(11):1439-52
pubmed: 21047773
J Clin Oncol. 2007 Aug 20;25(24):3719-25
pubmed: 17704421
Br J Cancer. 2007 Nov 5;97(9):1266-70
pubmed: 17923866
Dis Markers. 2016;2016:7340180
pubmed: 27051075
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
Ann Surg. 2013 Nov;258(5):784-92; discussion 792
pubmed: 24045450
Mol Cancer Ther. 2018 Jan;17(1):276-289
pubmed: 29051319
Virchows Arch. 2018 Feb;472(2):175-186
pubmed: 28918544
Cancer Microenviron. 2019 Apr;12(1):57-66
pubmed: 30834503
Br J Surg. 2017 Dec;104(13):1816-1828
pubmed: 28944954
PLoS One. 2015 Oct 06;10(10):e0139598
pubmed: 26440936
Ann Surg Oncol. 2010 Aug;17(8):2184-92
pubmed: 20217248
Br J Surg. 1996 Jan;83(1):107-11
pubmed: 8653330
Cancer. 2017 Nov 1;123(21):4106-4113
pubmed: 28885712
N Engl J Med. 1998 Dec 31;339(27):1979-84
pubmed: 9869669
Lancet Oncol. 2011 Jul;12(7):681-92
pubmed: 21684205
Cancer Immunol Immunother. 2016 Jun;65(6):651-62
pubmed: 27020682
Front Immunol. 2019 Feb 27;10:333
pubmed: 30873179
Gut. 2019 Nov;68(11):1918-1927
pubmed: 30852560
Medicine (Baltimore). 2015 Sep;94(39):e1631
pubmed: 26426650
Tumour Biol. 2015 Feb;36(2):1163-71
pubmed: 25722218
Ann Surg. 2005 Nov;242(5):684-92
pubmed: 16244542
Med Sci Monit. 2019 Aug 06;25:5850-5855
pubmed: 31385574
Genome Med. 2019 Jun 20;11(1):40
pubmed: 31221199
Int J Cancer. 2015 Aug 15;137(4):826-36
pubmed: 25604093
Ann Surg. 2003 Aug;238(2):197-202
pubmed: 12894012
J Clin Oncol. 2016 Aug 10;34(23):2721-7
pubmed: 27298411
Sci Rep. 2015 Oct 06;5:14756
pubmed: 26439902
Cancer Treat Rev. 2011 Feb;37(1):63-74
pubmed: 20570444
Br J Surg. 2001 Aug;88(8):1105-9
pubmed: 11488797
J Clin Invest. 2006 Feb;116(2):536-47
pubmed: 16453027
Ann Surg. 2020 Nov;272(5):814-819
pubmed: 32657924
Esophagus. 2020 Apr;17(2):113-121
pubmed: 31773415
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Clin Cancer Res. 2005 Nov 1;11(21):7683-91
pubmed: 16278388
Am J Surg. 2001 Aug;182(2):197-201
pubmed: 11574097
Surgery. 2016 Aug;160(2):331-40
pubmed: 27085684
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):298-313
pubmed: 32005946
Cancer Lett. 2016 Oct 1;380(2):525-33
pubmed: 25312939
Cancer Sci. 2013 Aug;104(8):1045-51
pubmed: 23648090
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Nat Commun. 2018 Nov 7;9(1):4672
pubmed: 30405103
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686